Carregant...
The Evolving Use of PI3 Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
B cells express four PI3K isoforms (p110α, p110β, p110γ, and p110δ) but have a unique dependence on p110δ for survival. The design of isoform-selective inhibitors is possible, and pharmacologic inhibition of p110δ is toxic to neoplastic CLL cells for both cell-intrinsic and cell-extrinsic reasons. I...
Guardat en:
| Publicat a: | Hematol Oncol Clin North Am |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8239250/ https://ncbi.nlm.nih.gov/pubmed/34174987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2021.03.009 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|